Insulet presents a high-quality compounding opportunity where a temporary execution challenge is obscuring fundamentally strong underlying business dynamics. The Type 2 diabetes segment represents a substantial untapped market for the company, while growing adoption of GLP-1 medications is likely to expand rather than cannibalize the opportunity for Insulet’s Omnipod insulin delivery system. Current valuation offers asymmetric upside potential, with more than 30% appreciation requiring only a modest re-rating to a level that remains well below historical multiples.
Wall Street has presented long-term investors with a rare mispricing of Insulet shares. The insulin pump manufacturer is currently trading at its lowest valuation multiple in a decade. This situation stems from a combination of a single-quarter operational miss layered atop an already over-discounted secular narrative, creating the kind of setup long-term investors actively seek: a fixable issue obscuring a durable, multiyear growth story.
Overblown concerns surrounding GLP-1 weight loss medications were already pressuring Insulet’s stock when an onboarding stumble in the U.S. Type 2 diabetes market triggered a more significant sell-off. Although second-quarter results beat key headline metrics across the board, Insulet shares declined approximately 20% on August 5 as the company cut its full-year revenue forecast. While the stock has been recovering, it has reclaimed less than half of its loss since that date.
The post-earnings drawdown was disproportionate to a guidance adjustment that was concentrated in a single distribution channel. Several sell-side analysts responded by downgrading the stock in the days that followed. Both the sell-off and subsequent downgrades represent an overreaction to a fixable execution issue. The bullish perspective here is intentionally contrarian.
Insulet does not face a demand problem. Last quarter’s revenue grew 23.5% year-over-year, exceeding consensus expectations. The company has not experienced market share loss, pricing pressure, or weakening end-market demand. Rather, during a 90-day patient onboarding process in the United States, Insulet successfully enrolled new Type 2 diabetes patients, but an excessive number discontinued use of the Omnipod insulin pump within their first three months of treatment. This represents a retention challenge that Insulet believes it can address by enhancing early patient support and follow-up protocols.
Insulet’s international growth has been accelerating, with revenue rising between 30% and 32%, and full-year earnings per share growth anticipated to exceed 30% compared to the prior year. A modest re-rating back toward a still-conservative 28x multiple yields a $196 price target, well below Insulet’s own historical range, and more than 30% above where the stock closed on August 31.
Additionally, GLP-1 weight loss medications are expanding Insulet’s future patient pool rather than contracting it, contrary to investor fears. Treatments such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound do not replace the insulin pumps Insulet manufactures. Instead, GLP-1 drugs bring more patients with Type 2 diabetes into active treatment, and a substantial share will ultimately require insulin and a delivery device like the Omnipod. Real-world data demonstrate that GLP-1 use approximately doubles the rate at which Type 2 patients initiate insulin therapy. As investors recognize this dynamic, the overhang on the stock may dissipate, further supporting valuation.
Insulet’s Competitive Advantages
Insulet’s Omnipod is a tubeless wearable insulin pump that automatically delivers insulin to individuals with diabetes. The device’s absence of tubing provides an advantage by reducing the risk of snagging on objects, a problem that affects tethered competitors. This design represents one of Omnipod’s key competitive differentiators. The device is also available through pharmacies rather than the more cumbersome medical equipment channel, and it integrates with leading glucose monitors such as Dexcom’s G7 and Abbott’s FreeStyle Libre 3 Plus, allowing patients to select their preferred glucose sensor rather than being locked into a particular brand.
The company operates a “razor-and-blade” recurring revenue model. Patients purchase 3-day wearable, disposable Omnipods, generating predictable, high-margin cash flow. This occurs with minimal working capital drag, since fulfillment runs through established pharmacy networks rather than capital-intensive durable equipment logistics. Insulet reaches more than 90% of U.S. pharmacies, allowing patients to access Omnipod for approximately $30 per month without being locked into long-term medical-equipment contracts. This makes adoption easier compared to many traditional insulin pumps.
The United States generates approximately 70% to 75% of revenue, but international markets are becoming increasingly significant as Insulet expands across Europe. The company’s balance sheet supports its growth trajectory. The company maintains minimal leverage, and gross margins of approximately 68% to 70% are expanding as automated manufacturing lines in Malaysia and the United States scale efficiency.
Examining the Latest Results
Insulet’s second-quarter results appeared strong on the surface. Revenue of $801.7 million exceeded the $787 million Wall Street consensus, while adjusted earnings of $1.66 per share beat estimates by more than 15%. Operating margins expanded by 140 basis points, and the number of U.S. physicians prescribing Omnipod grew 27%, providing strong evidence that demand remains healthy.
The challenge emerged in the fast-growing U.S. Type 2 diabetes business. Insulet has been successful at attracting more Type 2 patients to begin using Omnipod, with more than 40% of new U.S. starts coming from this group, but an excessive number were discontinuing during their first 90 days. In other words, the challenge involved not convincing doctors or patients to try Omnipod, but rather providing adequate support to help these newer, often first-time pump users transition successfully and remain engaged.
During the second-quarter conference call, CEO Ashley McEvoy acknowledged that the company should have identified the drop-off sooner. Insulet is responding with enhanced patient support, greater involvement from primary care physicians, and sales incentives that reward 90-day retention rather than simply signing up new users.
The slower ramp-up in users prompted Insulet to lower its forecast for U.S. Omnipod growth to a range of 17% to 19% from the previous 20% to 22%, bringing expected companywide revenue growth down to between 20% and 22% from approximately 23%. Importantly, the weakness was quite localized. Strong European demand, including the launch in Spain, led management to raise its international Omnipod growth forecast to a range of 30% to 32% from the prior range of 26% to 28%, while full-year adjusted earnings growth guidance increased to at least 30% from at least 25%.
Investors nevertheless punished the stock, sending it to a 52-week intraday low of $126.40. Several Wall Street firms subsequently downgraded Insulet, including Wells Fargo, JP Morgan, Leerink, and BTIG. BTIG analyst Marie Thibault, who downgraded Insulet to neutral from buy, noted that the report “left us with too many questions.” Shares have declined 48% year to date.
Unlocking the Type 2 Diabetes Market
Investors continue to price the stock as a Type 1 diabetes story, significantly underestimating its potential with Type 2 diabetes patients. When the Food and Drug Administration approved the Omnipod 5 for this group in September 2024, Insulet estimated its total addressable market expanded by 6 million people in the United States living with insulin-requiring Type 2 diabetes. Since more than 40% of new U.S. starts in the second quarter were Type 2 patients, evidence of the potential unlock is tangible, even though the onboarding process requires refinement.
“There’s a significant unmet need in this community,” McEvoy stated on the earnings call earlier this month. “We have really strong science, and [American Diabetes Association] guidelines are on our side. We do have synergy and learning from 25 years serving the Type 1 community. And as we stand here in August, we have tens of thousands of Type 2ers who are using Pod and getting fantastic results.”
That said, the CEO acknowledged meaningful differences between the two patient groups. Type 2 diabetes patients tend to be older, often have additional comorbidities, and may be covered by Medicare or Medicaid rather than private insurance. As part of efforts to improve retention, the company is scaling up pilot programs that provide proactive support during the “early moments of truth,” such as the first time a patient needs to change a Pod or refill a prescription. The company also expects increased deployment of its Omnipod Discover customer data platform to help patients recognize the benefits of therapy and maintain engagement.
“We do have some strong early proof points that give us confidence in the actions that we’re taking to have an impact on the important metrics that we need to drive,” Eric Benjamin, chief operating officer, stated on the call. The third quarter will provide an important early test of these initiatives. Investors should monitor 90-day patient retention closely. Management has set a lower bar, so an upside surprise could provide an early and credible signal of progress.
Another potential catalyst is the broader rollout of Abbott’s FreeStyle Libre 3 Plus. While older Omnipods could be used alongside a Libre glucose monitoring system, the new integrations allow the Omnipod 5 to receive glucose levels and automatically adjust insulin every five minutes.
Finally, management’s formal 2027 outlook, expected in the fourth quarter, should help investors look past the guidance reset and refocus on the longer-term trajectory. A confident multiyear growth outlook, particularly alongside improving Type 2 retention, could meaningfully restore confidence.
Competition is intensifying as both Tandem Diabetes Care and Medtronic pursue the same Type 2 opportunity. Insulet, however, enters this competitive landscape with meaningful advantages that should prove difficult to replicate. A less controllable risk lies in reimbursement. Omnipod’s attractive economics and ease of access depend partly on Medicare, Medicaid, and commercial insurers continuing to provide favorable coverage for insulin-pump therapy. Any meaningful tightening of coverage or reimbursement could make Omnipod more expensive for patients and reduce the size of its opportunity, regardless of Insulet’s execution quality.
Debunking the GLP-1 Threat
The concern that GLP-1 medications would decimate the insulin delivery market was largely a market myth driven by investor panic. In late 2023, the surging popularity of these drugs caused shares of medical device companies like Insulet to decline sharply, fueled by the narrative that GLP-1s would eliminate the need for insulin. This panic conflated the patient bases of Type 1 and Type 2 diabetes. In reality, GLP-1s do not cure or alter the absolute need for insulin in Type 1 diabetics, who maintain lifetime dependence on automated insulin delivery systems and represent Insulet’s core target market.
Furthermore, actual financial performance has debunked this “demand cliff” thesis. Rather than facing structural decline, Insulet has continued to generate substantial growth. Analysts note that GLP-1s can act as a gateway, extending the time Type 2 patients spend in specialized clinical care before eventually transitioning onto insulin pumps. While Insulet stock may experience volatility from unrelated issues, the underlying secular demand for tubeless insulin delivery remains highly resilient against the GLP-1 wave.
Valuation
Insulet’s stock trades at approximately 21x forward P/E, near its all-time valuation floor, well below its historical 10-year range of roughly 40x to 60x, and below the 30x to 40x multiples the market affords high-growth medtech peers despite Insulet’s comparable or superior top-line growth. Applying a conservative 28x forward P/E, which itself represents a discount to both the stock’s historical median and to peer multiples, to consensus 12-month forward EPS of $7.00 yields a price target of $196, representing more than 30% upside.
This conservatism is deliberate: even if the Type 2 onboarding issue takes several quarters to fully resolve, a 28x multiple does not require the market to underwrite a full return to Insulet’s historical 40x to 60x range, only a partial re-rating off the stock’s current trough.
Insulet combines exclusive product differentiation, massive Type 2 diabetes market expansion potential, and exceptional recurring revenue economics. With the stock trading at less than half its traditional valuation, the market has priced in something close to permanent impairment for what appears, based on evidence to date, to be a temporary operational issue. Meanwhile, clinical data undercuts the GLP-1 bear case, and Insulet’s balance sheet and margin profile show no cracks beyond the specific retention metric management flagged.
The stock’s valuation gap versus both Insulet’s own history and its peer group appears wide enough to absorb a slower-than-expected resolution without requiring a heroic re-rating. By the time that fog clears, likely as third-quarter retention data or the fourth-quarter long-range forecast reset lands, this entry point will likely have closed.
